One of the leading COVID-19 vaccine candidates currently in development is getting closer to a potential finish line. Pfizer (NYSE: PFE) said on Wednesday that the recruitment for the crucial U.S. phase 3 clinical trial of its BNT162b2 is more than 50% complete. The company is aiming to recruit 30,000 individuals for the trial.
The news was reported by Pfizer vaccine research and development scientist Dr. Nicholas Kitchin at a meeting of the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices.
BNT162b2, which Pfizer is developing in collaboration with Germany's BioNTech (NASDAQ: BNTX), is one of only a handful that is about to advance to phase 3 testing. Enrollment seems to be proceeding quickly; last week, the company said it had recruited over 11,000 individuals. At this pace, enrollment could be complete within only a few more weeks.
The company is confident it can recruit and conduct the late-stage trial quickly and effectively. Pfizer CEO Albert Bourla said in an Aug. 6 interview with The Washington Post that his company could start seeking regulatory approval for BNT162b2 as early as October; that, of course, assumes that the vaccine candidate proves to be efficacious in a relatively fast-moving late-stage trial.
The company has made arrangements with manufacturing partners to make the vaccine, if it is successful in the phase 3 trial and subsequently receives approval from major regulators. In July, Pfizer and BioNTech contracted with the U.S. government to supply up to 600 million doses.
Despite the positive news about BNT162b2, both Pfizer and BioNTech were down in midafternoon trading on Wednesday, in contrast to the gains of the wider market. Pfizer stock was off by 1.1%, while BioNTech had slumped 4.5%.
10 stocks we like better than Pfizer
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of August 1, 2020
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.